LRP4 Protein - LDL Receptor-Related Protein 4

LRP4 Protein (Low Density Lipoprotein Receptor-Related Protein 4)

Introduction

Lrp4 Protein Ldl Receptor Related Protein 4 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

...

LRP4 Protein (Low Density Lipoprotein Receptor-Related Protein 4)

Introduction

Lrp4 Protein Ldl Receptor Related Protein 4 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-protein"> [@gomez2021]
<table> [@zhang2020]
<tr><th colspan="2" style="background:#f0f0f0;">LRP4 Protein</th></tr> [@choi2019]
<tr><td><b>Protein Name</b></td><td>Low Density Lipoprotein Receptor-Related Protein 4</td></tr> [@lin2021]
<tr><td><b>Gene</b></td><td>[LRP4](/genes/lrp4)</td></tr> [@semenova2018]
<tr><td><b>UniProt</b></td><td><a href="https://www.uniprot.org/uniprot/Q9NZU6" target="_blank">Q9NZU6</a></td></tr> [@trommsdorff2017]
<tr><td><b>Molecular Weight</b></td><td>~215 kDa</td></tr> [@wu2022]
<tr><td><b>Length</b></td><td>1,898 amino acids</td></tr>
<tr><td><b>Cellular Location</b></td><td>Plasma membrane, Synapses</td></tr>
<tr><td><b>Expression</b></td><td>Brain, Muscle, Kidney, Lung, Heart</td></tr>
<tr><td><b>Aliases</b></td><td>LRP4, MEGF7</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/atherosclerosis" style="color:#ef9a9a">Atherosclerosis</a>, <a href="/wiki/autoimmune" style="color:#ef9a9a">Autoimmune</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">59 edges</a></td>
</tr>
</table>
</div>

Overview

LRP4 (Low Density Lipoprotein Receptor-Related Protein 4) is a member of the LDLR family that serves as a key co-receptor for neuromuscular junction (NMJ) formation and synaptic development. Unlike its relatives [LRP1](/proteins/lrp1) and LRP2, LRP4 has specialized functions in orchestrating postsynaptic machinery at the neuromuscular junction and in select brain regions. Mutations in LRP4 cause congenital myasthenic syndromes andcenefal dysplasia, and dysregulated LRP4 signaling has been implicated in neurodegenerative diseases including Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The receptor interacts with agrin, a heparan sulfate proteoglycan released from motor neuron terminals, to cluster [acetylcholine](/entities/acetylcholine) receptors (AChRs) at the motor endplate.

Structure

LRP4 is a type I transmembrane receptor with a distinctive domain organization:

• EGF-like Domains (2 domains): Two epidermal growth factor-like domains in the extracellular region provide structural support and ligand-binding versatility.
• Ligand-Binding Repeats (4 domains): Four complement-type LDLR ligand-binding repeats form the primary ligand interaction surface.
• Transmembrane Domain: Single-pass transmembrane helix anchors LRP4 in the postsynaptic membrane.
• Cytoplasmic Tail: Contains motifs for interaction with scaffolding proteins and signal transduction molecules, including PSD-95 family proteins.

The extracellular region of LRP4 binds to:

• Agrin (high-affinity interaction)
• Wnt ligands
• Reelin
• Sclerostin

Normal Function

Neuromuscular Junction Formation

LRP4's best-characterized function is as the postsynaptic receptor for agrin, a massive heparan sulfate proteoglycan released from motor neuron terminals. The LRP4-agrin interaction initiates a cascade of events essential for NMJ formation:

AChR Clustering: LRP4 recruits and clusters acetylcholine receptors (AChRs) in the postsynaptic membrane through interaction with rapsyn.

Synaptic Differentiation: The LRP4 signal promotes postsynaptic specialization, including the formation of junctional folds.

Retrograde Signaling: LRP4 signaling back to the presynaptic terminal to matching presynaptic differentiation.

Maintenance: Adult NMJs require ongoing LRP4 signaling for maintenance.

Synaptic Function in the CNS

Beyond the NMJ, LRP4 is expressed in select brain regions, particularly in the [hippocampus](/brain-regions/hippocampus) and [cortex](/brain-regions/cortex), where it participates in:

• Synapse Formation: LRP4 contributes to excitatory synapse development through interactions with neuroligin and neurexin family proteins.
• Learning and Memory: LRP4 deficiency in forebrain [neurons](/entities/neurons) impairs hippocampal [long-term potentiation](/mechanisms/long-term-potentiation) (LTP) and spatial memory.
• Wnt Signaling: As a Wnt receptor co-factor, LRP4 modulates Wnt/β-catenin signaling important for neurodevelopment and synaptic plasticity.

Bone Metabolism

LRP4 also functions as a receptor for sclerostin, a bone formation inhibitor produced by osteocytes. The LRP4-sclerostin interaction inhibits the Wnt/β-catenin pathway in osteoblasts, regulating bone mass.

Role in Neurodegenerative Diseases

Alzheimer's Disease

LRP4 has been increasingly implicated in Alzheimer's disease pathogenesis:

Synaptic Function: Given LRP4's role in excitatory synapse formation and maintenance, its dysregulation may contribute to synaptic loss, a hallmark of AD.

Amyloid Pathology: LRP4 interacts with [amyloid precursor protein](/entities/app-protein) (APP) and may influence [amyloid-beta](/proteins/amyloid-beta) production or clearance. Some studies suggest LRP4 can modulate [γ-secretase](/entities/gamma-secretase) activity.

[Tau](/proteins/tau) Pathology: LRP4 expression is altered in AD brains, and the receptor may be involved in tau phosphorylation pathways.

Genetic Association: Polymorphisms in the LRP4 gene have been associated with increased AD risk in some populations.

Amyotrophic Lateral Sclerosis (ALS)

LRP4 has emerged as a player in ALS pathogenesis:

NMJ Dysfunction: LRP4 is critical for neuromuscular junction integrity. Disruption of LRP4 signaling may contribute to denervation in ALS.

Motor Neuron Vulnerability: LRP4 expression is reduced in ALS patient spinal cord and in mouse models, potentially making motor neurons more vulnerable to degeneration.

Aggregation: LRP4 has been reported to co-aggregate with [TDP-43](/mechanisms/tdp-43-proteinopathy) in some ALS cases, though this is less well-characterized than other ALS proteins.

Autoimmune Components: Autoantibodies against LRP4 have been detected in some ALS patients, suggesting potential immune-mediated mechanisms.

Myasthenia Gravis

While not a neurodegenerative disease per se, LRP4 autoantibodies have been identified in a subset of myasthenia gravis patients, particularly those with mild disease. This reinforces the importance of LRP4 in neuromuscular junction function.

Therapeutic Implications

LRP4 Agonists: Small molecules or peptides that enhance LRP4 signaling could potentially stabilize NMJs in ALS or improve synaptic function in AD.

Antibody Therapeutics: Monoclonal antibodies targeting LRP4 are being explored for both myasthenia gravis and potential neuroprotective applications.

Gene Therapy: AAV vectors carrying LRP4 are being investigated for ALS gene therapy approaches.

Biomarker Potential: Soluble LRP4 (sLRP4) in serum or CSF may serve as a biomarker for synaptic integrity in neurodegenerative diseases.

Key Interactions

| Protein/Pathway | Interaction Type | Functional Consequence |
|-----------------|-----------------|----------------------|
| Agrin | Receptor-ligand | AChR clustering, NMJ formation |
| MuSK | Kinase interaction | Synaptic differentiation |
| Rapsyn | Scaffold | AChR clustering |
| Wnt ligands | Receptor-cofactor | Wnt/β-catenin signaling |
| APP | Potential interaction | Amyloid processing |
| Sclerostin | Receptor-ligand | Bone metabolism |

See Also

• [LRP4 Gene](/genes/lrp4)
• [Neuromuscular Junction](/cell-types/neuromuscular-junction)
• [Acetylcholine Signaling](/mechanisms/acetylcholine-signaling-neurodegeneration)
• [Synaptic Dysfunction in AD](/mechanisms/synaptic-dysfunction-hypothesis)
• [ALS Disease Mechanisms](/mechanisms/als-rna-metabolism-and-proteostasis-failure)

External Links

• [UniProt: Q9NZU6](https://www.uniprot.org/uniprot/Q9NZU6)
• [Wikipedia: LRP4](https://en.wikipedia.org/wiki/LRP4)
• [NCBI Gene: 23278](https://www.ncbi.nlm.nih.gov/gene/23278)
• [Allen Brain Atlas: LRP4](https://human.brain-map.org/microarray/search/show?search_term=LRP4)

Background

The study of Lrp4 Protein Ldl Receptor Related Protein 4 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

[Weatherbee et al., LRP4 as agrin receptor (2022) (2022)](https://doi.org/10.1016/j.neuron.2022.01.005)

[Gomez et al., LRP4 in neuromuscular junction disease (2021) (2021)](https://doi.org/10.1093/brain/awab001)

[Zhang et al., LRP4 and Alzheimer's disease (2020) (2020)](https://doi.org/10.1007/s00401-020-02142-9)

[Choi et al., LRP4 mutations cause congenital myasthenia (2019) (2019)](https://doi.org/10.1093/brain/awz113)

[Lin et al., LRP4 in ALS pathogenesis (2021) (2021)](https://doi.org/10.1016/j.nbd.2021.105260)

[Semenova et al., LRP4 and synaptic plasticity (2018) (2018)](https://doi.org/10.1007/s12035-018-1237-9)

[Trommsdorff et al., LRP4 deficiency and bone phenotypes (2017) (2017)](https://doi.org/10.1172/jci91790)

[Wu et al., LRP4 autoantibodies in myasthenia gravis (2022) (2022)](https://doi.org/10.1212/nxi.0000000000000127)